How Brivaracetam was developed and where the drug comes from

Brivaracetam/Brivaracetam is a new generation of anti-epileptic drugs developed by UCB Pharmaceuticals in Belgium. It is a structurally optimized derivative of levetiracetam and is considered an "upgraded" SV2A (synaptic vesicle protein 2A) ligand. After discovering that levetiracetam can inhibit abnormal neuronal firing by acting on the SV2A protein, UCB continues to explore improved molecules with stronger binding force and less side effects. The research team screened hundreds of similar compounds and finally identified Brivaracetam as a drug candidate. Its molecular structure maintains its original active skeleton while enhancing its lipid solubility, allowing it to cross the blood-brain barrier more quickly, thereby exerting a stable neuromodulatory effect in the brain.

In terms of pharmacological mechanism, the binding affinity of brivaracetam to SV2A protein is 15 to 30 times higher than that of levetiracetam, which means that it can achieve better anti-epileptic effects at a lower dose. SV2A is an important regulatory protein of synaptic vesicles and is closely related to the release of neurotransmitters. Brivaracetam fundamentally reduces synchronized neuronal firing during epileptic seizures by inhibiting the excessive release of presynaptic neurotransmitters.

The development process of Brivaracetam fully reflects the transformation of modern drugs from "experience-oriented" to "precision target-oriented". The UCB scientific team used molecular dynamics simulation and structural biology techniques to optimize the affinity region of the drug at the synaptic protein binding site, so that the drug not only showed excellent anti-seizure effects in animal experiments, but also showed good safety and tolerability in clinical trials. The advent of Brivaracetam is regarded as an important progress in the field of neuropharmacology. It not only improves the seizure control rate of epilepsy patients, but also shows advantages in cognitive function and behavioral stability.

Reference materials:https://www.briviact.com/